David Baker - 23Andme Holding Chief Engineering
| ME Stock | USD 3.23 0.08 2.54% |
Executive
David Baker is Chief Engineering of 23Andme Holding Co
| Age | 53 |
| Address | 349 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 938 6300 |
| Web | https://www.23andme.com |
David Baker Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Baker against 23Andme Holding stock is an integral part of due diligence when investing in 23Andme Holding. David Baker insider activity provides valuable insight into whether 23Andme Holding is net buyers or sellers over its current business cycle. Note, 23Andme Holding insiders must abide by specific rules, including filing SEC forms every time they buy or sell 23Andme Holding'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Baker over two months ago Acquisition by David Baker of 2400 shares of Bassett Furniture at 17.55 subject to Rule 16b-3 | ||
David Baker over two months ago Disposition of 832 shares by David Baker of Aspen Technology at 234.14 subject to Rule 16b-3 | ||
David Baker over three months ago Acquisition by David Baker of 4002 shares of Aspen Technology subject to Rule 16b-3 |
23Andme Holding Management Efficiency
The company has Return on Asset (ROA) of (0.2577) % which means that for every 100 dollars spent on asset, it generated a loss of $0.2577. This is way below average. Likewise, it shows a return on total equity (ROE) of (1.5421) %, which implies that it produced no returns to current stockholders. 23Andme Holding's management efficiency ratios could be used to measure how well 23Andme Holding manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.86. In addition to that, Return On Capital Employed is expected to decline to -1.26. At present, 23Andme Holding's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christopher Freeman | Guardant Health | 50 | |
| Sharon Vidal | Illumina | N/A | |
| John JD | Guardant Health | 51 | |
| James Polewaczyk | IDEXX Laboratories | 60 | |
| Ankur CPA | Illumina | 48 | |
| John Saia | Guardant Health | 51 | |
| John Kohl | Agilent Technologies | N/A | |
| Scott Davies | Illumina | N/A | |
| Joydeep MBA | Illumina | 53 | |
| Gretchen Weightman | Illumina | N/A | |
| Adam Laponis | Twist Bioscience Corp | 47 | |
| Yvonne Mackie | Agilent Technologies | N/A | |
| Michael Johnson | IDEXX Laboratories | 46 | |
| Ryan Snyder | Thermo Fisher Scientific | N/A | |
| Ankur Dhingra | Illumina | 48 | |
| Charles Esq | Illumina | 65 | |
| CPA BCom | Genetic Technologies | 57 | |
| Jakob Wedel | Illumina | N/A | |
| James Thorburn | Twist Bioscience Corp | 68 | |
| Kristen Garvey | Waters | N/A | |
| Mena Farag | Illumina | N/A | |
Management Performance
| Return On Equity | -1.54 | ||||
| Return On Asset | -0.26 |
23Andme Holding Leadership Team
Elected by the shareholders, the 23Andme Holding's board of directors comprises two types of representatives: 23Andme Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 23Andme. The board's role is to monitor 23Andme Holding's management team and ensure that shareholders' interests are well served. 23Andme Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 23Andme Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anne Wojcicki, CEO, CoFounder | ||
| Joseph Selsavage, Interim Officer | ||
| Katie Watson, Vice Communications | ||
| MB ChB, Executive Officer | ||
| Wade Walke, VP Relations | ||
| Jennifer Low, Head Development | ||
| JD Esq, Chief Secretary | ||
| Kent Hillyer, Vice Operations | ||
| Jennifer MD, Head Development | ||
| Reza MBA, Chief Officer | ||
| Adam Auton, Vice Genetics | ||
| Guy Chayoun, Vice Counsel | ||
| Jacquie JD, General Officer | ||
| Daniel Chu, Chief Officer | ||
| Jonathan Ward, Chief Officer | ||
| Savita Pillai, Vice People | ||
| David Baker, Chief Engineering | ||
| William Richards, Head Discovery | ||
| Eli Fry, Vice Operations |
23Andme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 23Andme Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.54 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (1.78) % | ||||
| Current Valuation | 27.36 M | ||||
| Shares Outstanding | 19.01 M | ||||
| Shares Owned By Insiders | 3.65 % | ||||
| Shares Owned By Institutions | 33.33 % | ||||
| Number Of Shares Shorted | 1.2 M | ||||
| Price To Earning | (3.48) X | ||||
| Price To Book | 0.81 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in 23Andme Holding Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 23Andme Holding. If investors know 23Andme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 23Andme Holding listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (122.52) | Revenue Per Share 8.224 | Quarterly Revenue Growth (0.34) | Return On Assets (0.26) | Return On Equity (1.54) |
The market value of 23Andme Holding is measured differently than its book value, which is the value of 23Andme that is recorded on the company's balance sheet. Investors also form their own opinion of 23Andme Holding's value that differs from its market value or its book value, called intrinsic value, which is 23Andme Holding's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 23Andme Holding's market value can be influenced by many factors that don't directly affect 23Andme Holding's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 23Andme Holding's value and its price as these two are different measures arrived at by different means. Investors typically determine if 23Andme Holding is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 23Andme Holding's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.